Cirrhosis treatment has changed dramatically in the past decade. Where doctors once considered the scarred liver a one-way street toward transplant or end-of-life care, researchers now have evidence that fibrosis and even established cirrhosis can partially reverse under the right conditions. The first drug specifically approved for a major cause of cirrhosis reached the market in 2024, and several other approaches targeting scar tissue, portal pressure, gut bacteria, and liver-cell regeneration are in advanced clinical trials or already reshaping care. None of these are miracle cures, but taken together they represent a genuine shift from managing symptoms to treating the disease itself.
Cirrhosis Can Reverse, and That Changes Everything
For most of the twentieth century, medical textbooks described cirrhosis as irreversible. That view started cracking once researchers began collecting serial liver biopsies from patients whose underlying disease had been treated. In hepatitis C, for example, patients who achieved a sustained viral cure showed striking improvements: in one analysis of 153 patients with biopsy-confirmed cirrhosis, about half showed histological reversal after antiviral therapy. The more effectively the virus was cleared, the more likely fibrosis was to regress.1Gastroenterology. Reversibility of hepatic fibrosis and cirrhosis Similar patterns have been documented in other causes of liver injury, including autoimmune hepatitis and alcohol-related liver disease, across multiple clinical studies with repeat biopsies.2PubMed Central. Reversal of liver cirrhosis: current evidence and expectations
This does not mean every scarred liver bounces back. Advanced cirrhosis with thick, heavily cross-linked collagen bands and severely distorted architecture is much harder to undo than earlier-stage fibrosis. And reversal depends on removing or controlling the original insult, whether that is a virus, alcohol, excess fat, or an autoimmune attack. Still, the proof that the liver can rebuild its structure opened the door for a new generation of therapies designed not just to slow progression but to actively encourage the scar to dissolve.
Resmetirom and the First Approved Treatment for Fatty Liver Disease
Metabolic dysfunction-associated steatohepatitis, or MASH (formerly called NASH), is now one of the leading causes of cirrhosis worldwide, driven by the rise in obesity and type 2 diabetes. Until 2024, there was no approved drug specifically for it. Resmetirom changed that. It is an oral medication that selectively activates a thyroid hormone receptor concentrated in the liver, ramping up the organ’s ability to burn fat, calm inflammation, and break down the lipids that drive cell injury.3PubMed Central. A new liver-targeted agonist of thyroid hormone receptor beta resmetirom in treating MASLD/MASH: From mechanism to therapy
The pivotal trial, called MAESTRO-NASH, showed that resmetirom met both of its primary goals: resolving the inflammatory component of MASH without worsening fibrosis.4PubMed Central. Resmetirom: The First Disease-Specific Treatment for MASH A systematic review and meta-analysis also found that the drug reduced markers tied to active scar formation, including liver stiffness and a collagen fragment called PRO-C3 that reflects net fibrosis production.5Scientific Reports. Efficacy and safety of Resmetirom, a selective thyroid hormone receptor-β agonist, in the treatment of metabolic dysfunction-associated steatotic liver disease (MASLD): a systematic review and meta-analysis Because it targets the liver specifically, it avoids most of the heart-racing, bone-thinning side effects associated with broader thyroid hormone therapies.
Resmetirom is not a fix for all cirrhosis. It is designed for the metabolic-fatty-liver pathway. But given that MASH is projected to become the leading indication for liver transplant in the coming years, having a disease-specific drug is a big deal, and several other molecules targeting the same pathway are in development.
GLP-1 Drugs and the Liver
You may know GLP-1 receptor agonists as diabetes or weight-loss drugs. Semaglutide and its relatives have been making headlines for their effects on blood sugar and body weight, but researchers have been watching their impact on the liver for over a decade. Early animal work showed that exenatide, one of the first GLP-1 agonists, reversed fatty liver in obese mice by improving insulin sensitivity.6PubMed Central. Exendin-4, a glucagon-like protein-1 (GLP-1) receptor agonist, reverses hepatic steatosis in ob/ob mice Follow-up studies found that the benefit appears to work through a protein called SIRT1, which helps regulate fat storage and inflammation in liver cells.7PubMed. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis
In humans, the picture is promising but still unfolding. Semaglutide has shown meaningful reductions in liver inflammation and steatosis in clinical trials for MASH, though the evidence on whether it can improve established fibrosis is less clear-cut. These drugs are not yet approved specifically for liver disease, but many hepatologists are already prescribing them off-label in patients who have both diabetes and fatty liver. It is worth watching this space because several large phase 3 trials are running, and the results could reshape treatment guidelines within a few years.
Drugs That Target Scar Tissue Directly
While resmetirom and GLP-1 drugs work by reducing the upstream damage that triggers scarring, another class of therapies aims at the scar itself. The liver builds fibrosis through specialized cells called hepatic stellate cells, which, when activated by injury, pump out collagen and other structural proteins. Shut these cells down or dissolve the collagen they produce, and fibrosis should regress even if some underlying injury remains.
One approach targets galectin-3, a protein that helps drive stellate cell activation and collagen deposition. In rats with chemically induced cirrhosis, galectin inhibitors promoted collagen breakdown and reversed the architectural distortion that defines cirrhosis, even while the toxic exposure continued.8PubMed Central. Regression of Fibrosis and Reversal of Cirrhosis in Rats by Galectin Inhibitors in Thioacetamide-Induced Liver Disease A galectin-3 inhibitor called belapectin reached human trials for portal hypertension tied to MASH cirrhosis, and while the overall results were mixed, a pre-specified subgroup without esophageal varices showed a significant reduction in portal pressure, suggesting the drug may work best earlier in the disease.
Another target is LOXL2, an enzyme that chemically cross-links collagen fibers and makes scar tissue tougher and harder to break down. A compound called PAT-1251 was tested in mice with bile-duct-driven fibrosis and achieved up to about a 78% reduction in collagen deposits at higher doses.9PubMed Central. A novel cell-permeable LOXL2 inhibitor PAT-1251 potently suppresses biliary liver fibrosis via collagen crosslinking-dependent and -independent mechanisms An earlier LOXL2-targeting antibody failed in a large human trial, so researchers are cautious, but PAT-1251 works through a different mechanism and the animal data have rekindled interest.
These antifibrotic strategies are still mostly in early clinical development. The challenge is that fibrosis is a repair process, so drugs that block it need to be selective enough not to impair wound healing elsewhere in the body. But the concept of directly dissolving liver scar tissue is no longer theoretical.
Managing Portal Hypertension Without Transplant
Much of the suffering in cirrhosis comes not from the scar tissue itself but from what it does to blood flow. Scarring increases resistance inside the liver’s blood vessels, backing up pressure in the portal vein. That portal hypertension leads to swollen esophageal veins (varices) that can bleed catastrophically, fluid buildup in the abdomen, and confusion from toxins the liver can no longer filter. Traditionally, the main options have been non-selective beta-blockers like propranolol and procedures to band or shunt distended veins.
Carvedilol has emerged as the preferred beta-blocker for this setting. Unlike propranolol, it also has mild anti-alpha-adrenergic activity, which reduces resistance inside the liver’s own vessels. Clinical evidence shows it achieves better portal pressure reduction than propranolol in patients with compensated cirrhosis and lowers the risk of a first decompensation event.10PubMed. Carvedilol as the new non-selective beta-blocker of choice in patients with cirrhosis and portal hypertension A meta-analysis found that carvedilol performed at least as well as endoscopic variceal ligation for preventing first variceal bleeds and appeared to do so with a trend toward superiority, though confidence intervals were wide.11PubMed Central. Carvedilol for prevention of variceal bleeding: a systematic review and meta-analysis
Statins are an even more surprising entrant. Beyond cholesterol lowering, statins boost nitric oxide production in the liver’s blood vessel lining, which relaxes the vessels and reduces sinusoidal resistance. Clinical data suggest statin use in cirrhosis patients can reduce portal pressure, decrease variceal bleeding risk, and improve both decompensation-free and overall survival.12PubMed Central. Review of the role of statins in cirrhosis and portal hypertension Statins were long avoided in liver disease patients due to concerns about hepatotoxicity, but accumulating evidence suggests they are safe at standard doses in compensated cirrhosis. Multiple randomized trials are now testing simvastatin and atorvastatin specifically in this population.
Treating the Gut to Help the Liver
The gut and the liver are connected by the portal vein, which carries everything absorbed from the intestines directly to the liver. In cirrhosis, a leaky gut barrier lets bacteria and their toxins slip into the bloodstream, fueling the chronic inflammation that drives both liver damage and many of cirrhosis’s worst complications, including hepatic encephalopathy, the brain fog and confusion caused by ammonia and other toxins the liver fails to clear.
Rifaximin, a barely absorbed antibiotic that acts almost entirely within the gut, has been used for years to prevent recurrent hepatic encephalopathy. It works in part by reducing the bacteria that produce ammonia and in part by tamping down endotoxin levels, which calms the inflammatory cascade. In one study of patients with decompensated cirrhosis, four weeks of rifaximin lowered endotoxin activity along with markers of macrophage activation, suggesting it reduces the inflammatory signaling between gut and liver.13PubMed Central. Rifaximin Alleviates Endotoxemia with Decreased Serum Levels of Soluble CD163 and Mannose Receptor and Partial Modification of Gut Microbiota in Cirrhotic Patients
A more radical approach is fecal microbiota transplantation, which replaces a patient’s gut bacteria with those from a healthy donor. Early trials in cirrhosis patients with hepatic encephalopathy have shown cognitive improvements and fewer serious adverse events compared to standard care.14PubMed Central. Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions The idea is that shifting the microbial community toward species that produce less ammonia and help maintain gut barrier integrity can reduce both the toxin burden and the inflammatory load on the liver.15PubMed. Fecal microbiota transplantation in hepatic encephalopathy: a systematic review This remains experimental, and questions about donor screening, dosing, and long-term safety are still being worked out, but it represents one of the more creative avenues in cirrhosis care.
Long-Term Albumin Infusions
Albumin is a protein made by the liver that keeps fluid inside blood vessels and carries toxins, hormones, and drugs through the bloodstream. In advanced cirrhosis, albumin levels drop, contributing to fluid retention and systemic inflammation. Giving albumin intravenously during acute complications like spontaneous bacterial peritonitis has been standard for decades, but a newer idea is using regular albumin infusions over months as a disease-modifying therapy.
The ANSWER trial enrolled patients with decompensated cirrhosis and compared standard medical treatment alone to standard treatment plus weekly albumin infusions. The albumin group had significantly higher survival at 18 months, with roughly a 38% reduction in the risk of death.16PubMed. Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial The trial suggested albumin may work not just by pulling fluid out of the abdomen but by restoring some of the liver’s regulatory functions. However, not every subsequent study has confirmed the mechanism. A smaller trial looking at targeted albumin infusions in hospitalized patients found no improvement in inflammatory markers or cardiovascular function compared to standard care, raising questions about which patients benefit and how the albumin needs to be dosed.17PubMed Central. Targeted Albumin Infusions Do Not Improve Systemic Inflammation or Cardiovascular Function in Decompensated Cirrhosis
This disagreement is an active area of research. The current thinking is that long-term, regular albumin infusions in outpatients may help, but short targeted infusions in hospitalized patients may not have the same effect. More trials are underway to sort out the dose, duration, and patient selection.
Stem Cells and Regenerative Approaches
Regenerative medicine has an obvious appeal for cirrhosis: if you could coax the liver to grow new, functional tissue, you might bypass the need for transplant entirely. The most studied approach so far uses mesenchymal stem cells, typically derived from umbilical cord tissue. These cells do not turn into liver cells in any meaningful number, but they appear to act as biological pharmacies, releasing anti-inflammatory signals that calm stellate cells and promote repair.
A randomized controlled trial followed patients with decompensated cirrhosis who received umbilical-cord-derived mesenchymal stem cells alongside standard treatment. Over 48 weeks, the stem cell group showed improved liver function on multiple measures, including serum albumin, clotting ability, and bilirubin levels.18PubMed Central. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long-term follow-up analysis of the randomized controlled clinical trial Other groups have explored using growth factors like G-CSF to mobilize the patient’s own bone marrow stem cells, with case reports suggesting that this can activate liver progenitor cells in patients with acute-on-chronic liver failure.19PubMed. A case of granulocyte-colony stimulating factor/plasmapheresis-induced activation of granulocyte-colony stimulating factor-positive hepatic progenitors in acute-on-chronic liver failure
These results are encouraging but preliminary. The trials are small, follow-up periods are limited, and questions remain about optimal cell sources, dosing schedules, and whether the benefits persist. Stem cell therapy for cirrhosis has not entered routine clinical use anywhere in the world, though several larger trials are recruiting.
Artificial Liver Support Devices
When the liver fails acutely, often on top of existing cirrhosis, there is a critical window where support therapies can buy time for the organ to recover or for a transplant to become available. Artificial liver support devices attempt to fill this gap. The best-known system, called MARS (molecular adsorbent recirculating system), filters albumin-bound toxins from the patient’s blood. Therapeutic plasma exchange, which swaps out a patient’s plasma for fresh donor plasma, tackles both toxins and inflammatory mediators.
Both MARS and plasma exchange are well tolerated and can improve encephalopathy and stabilize blood pressure in the short term.20Current Opinion in Critical Care. Artificial liver support in acute and acute-on-chronic liver failure The problem is that randomized trials have not shown a clear survival benefit for either device in acute liver failure or acute-on-chronic liver failure. One study did find that patients in earlier stages of acute-on-chronic failure seemed to respond better, and that three to five sessions appeared to be a reasonable treatment course, suggesting timing matters more than was previously appreciated.21PubMed Central. Outcome of patients with different stages of acute-on-chronic liver failure treated with artificial liver support system
Bioartificial liver devices, which incorporate actual liver cells into the filtering system to provide not just toxin removal but some synthetic and regulatory function, remain largely experimental.22PubMed Central. Artificial and bioartificial liver support The concept is sound, but scaling up a living-cell cartridge that works reliably in a clinical setting has proven extremely difficult.
RNA Interference and Gene Editing on the Horizon
Further down the development pipeline, researchers are exploring whether they can silence the genes that drive fibrosis using RNA interference or, more ambitiously, correct them with gene editing tools like CRISPR. The idea is to deliver small RNA molecules or gene-editing components directly to stellate cells, switching off the signals that tell them to produce collagen.23PubMed. How successful has targeted RNA interference for hepatic fibrosis been? Both synthetic small interfering RNAs and longer-lasting expressed RNA constructs have shown the ability to reduce fibrosis in animal models.
The major hurdle is delivery. Getting these molecules into the right cells in a scarred, architecturally distorted liver without damaging healthy tissue requires precision. Nanoparticle delivery systems designed to home in on stellate cells are an active area of work, combining lipid or polymer shells with targeting ligands that recognize receptors on the cell surface.24PubMed Central. Nanogene editing drug delivery systems in the treatment of liver fibrosis No gene-based antifibrotic therapy has reached human trials yet, but the pace of nanoparticle development in other liver diseases, particularly for cholesterol-lowering therapies already on the market, gives reason to think the delivery problem is solvable.
Better Monitoring Without Repeated Biopsies
A treatment revolution is only as useful as your ability to tell whether it is working. Liver biopsy has been the gold standard for staging fibrosis, but it is invasive, painful, and samples only a tiny sliver of the organ. Newer approaches aim to track disease progression and treatment response through a simple blood draw.
Liquid biopsy techniques analyze fragments of DNA shed by dying liver cells into the bloodstream. Specific methylation patterns on that circulating DNA can distinguish healthy liver tissue from inflamed or fibrotic tissue, potentially serving as a biomarker for treatment response and for identifying patients at highest risk of progressing.25Journal of Clinical and Translational Hepatology. Liquid Liver Biopsy for Disease Diagnosis and Prognosis Meanwhile, machine learning models are being trained on large multi-omics datasets to distinguish patients with simple fatty liver from those progressing to MASH. One ensemble model achieved strong predictive accuracy across multiple independent patient groups and identified a macrophage marker called DTNA as particularly useful for classifying disease stage.26npj digital medicine. Integrating multi-omics and machine learning systematically deciphers cellular heterogeneity and fibrotic regulatory networks in the progression from MASLD to MASH
These tools are not yet standard clinical practice, but they matter for the treatment story. If doctors can monitor fibrosis regression in near-real time through blood tests rather than waiting years between biopsies, they can adjust drug therapies faster and run clinical trials more efficiently, which accelerates everything else.
How Transplant Itself Is Changing
For patients with advanced cirrhosis that does not respond to medical therapy, liver transplant remains the definitive treatment. But the supply of donor organs has always been the bottleneck, and new preservation technology is expanding the pool. Normothermic machine perfusion keeps a donor liver warm and metabolically active outside the body, pumping oxygenated blood through it at body temperature rather than packing it on ice.
Randomized trials have shown that this approach reduces graft injury compared to traditional cold storage and improves the rate at which donated livers are actually used rather than discarded.27PubMed. Long-term outcomes after normothermic machine perfusion in liver transplantation-Experience at a single North American center One center reported that after adopting the technology, it was able to accept livers from older donors, from greater distances, and with longer warm-ischemia times than previously considered safe. Preservation times now routinely exceed 24 hours, giving surgical teams logistical flexibility that was impossible with ice alone.28JAMA Surgery. Improved Outcomes and Resource Use With Normothermic Machine Perfusion in Liver Transplantation
For patients on the waiting list, this means more livers are becoming available, and organs that would once have been turned down are being transplanted successfully. It does not eliminate the organ shortage, but it narrows the gap meaningfully. Some researchers are even exploring whether perfusion machines could be used to treat marginal livers with drugs or gene therapies before transplanting them, turning the preservation step into a treatment step.